Slide 1: Faster, more accurate gold analysis
Faster, more accurate gold analysis FY26 Financial Results 11 August 2026 Dirk Treasure, Managing Director and CEO Brett Coventry, CFO
Slide 2: Important notice
Important notice The material in this presentation has been prepared by Chrysos Corporation Limited (ASX: C79) (“Chrysos” or the “Group") and is general background information about Chrysos’ current activities as at the date of this presentation. The information is given in summary form and does not
Slide 3: Agenda
Agenda FY26 Results presented by Managing Director and CEO, Dirk Treasure, and CFO, Brett Coventry 01 FY26 highlights Slides 4–8 02 Financial performance Slides 9–17 03 Growth opportunity Slides 18–23 04 FY27 guidance and outlook Slides 24–30 05 Appendices Slides 31–40 CHRYSOS CORPORATION LIMITED |
Slide 4: Financial and operating highlights
Financial and operating highlights Achieved higher end of FY26 Revenue and EBITDA guidance $88.1m $27.2m Total Revenue EBITDA • +33% growth YoY versus FY25 ($66.1m) • +68% growth YoY FY25 ($16.1m) • MMAP Revenue of $62.5m (+12% YoY), AAC Revenue of $25.5m (+153% YoY) • Improved EBITDA Margin of 31%
Slide 5: PhotonAssay sample volumes
PhotonAssay sample volumes Continued conversion to PhotonAssay and industry activity driving samples PhotonAssayTM Samples Analysed Quarterly Activity Commentary Samples Processed (Quarterly) 3,500 ■ Sustained PhotonAssayTM demand - monthly throughput surpassed a record 1m samples and has held above
Slide 6: Sample volumes scaling ahead of the fleet
Sample volumes scaling ahead of the fleet Rising utilisation, fleet expansion and software-led throughput gains are driving record sample volumes PhotonAssayTM Samples Analysed Quarterly Activity Commentary ■ Quarterly PhotonAssay sample volumes grew~2.4× over the last 24 months, from ~1.3m in Q4 FY
Slide 7: Executing on our global PhotonAssay roll out
Executing on our global PhotonAssayTM roll out Strengthening relationships with key miners and laboratories 46 Units Deployed1 FY26 Activity Seven units deployed in FY26, bringing total deployed units to 46: Three units deployed with ALS across Australia and Canada One unit deployed for MSA at
Slide 8: Targeted sales strategy
Targeted sales strategy Increasing utilisation supports sustained gross profit per unit Two-pronged sales approach Quarterly PhotonAssayTM samples analysed 3,500,000 Laboratory Mine Site 3,000,000 Hub & Spoke Deployment Strategy Minesite Deployment Strategy 2,500,000 2,000,000 Laboratory partnership
Slide 9: FY26 Financial Summary
FY26 Financial Summary [Insert]
Slide 10: Diversifying regional revenues
Diversifying regional revenues Continued adoption of PhotonAssayTM and increased industry activity continue to drive growth Revenue1 by Region $100,000 33% $90,000 $80,000 ■ Revenue1 of $88.1m, up 33% YoY (FY25: $66.1m), driven by continued adoption of PhotonAssayTM technology and elevated industry
Slide 11: Predictable base revenue with accelerating upside
Predictable base revenue with accelerating upside MMAP provides a stable revenue floor, while AAC captures accelerating upside from rising utilisation MMAP, AAC and Other Revenue $100,000 +33%1 $90,000 ■ Minimum Monthly Assay Payments (MMAP) provide predictable and $80,000 sustainable minimum revenu
Slide 12: Revenue & profitability
Revenue & profitability EBITDA margin growing with scale and utilisation #039;000 FY25 FY26 % change Revenue 65,990 87,999 1 Total Revenue of $88.1m: +33% YoY, reflecting continued global adoption of Revenue from consumables 122 111 PhotonAssay , strong gold market conditions and record utilisation acr
Slide 13: Foreign exchange impact on FY26 result
Foreign exchange impact on FY26 result Reported results absorbed a material FX headwind, yet still delivered at the top of guidance Reported vs constant currency (A$m) ■ FY26 guidance was set in August 2025 on constant-currency FX Reported Constant currency assumptions, with approximately 55% of Gro
Slide 14: Unit metrics and financial leverage
Unit metrics and financial leverage Strong unit metrics across deployed units Unit Metrics1 Consistent 70-80% gross profit margins sustained across FY24, FY25 and 2,000,000 FY26, reflecting durable revenue and disciplined unit cost 1,800,000 1,600,000 FY26 unit margins held firm even as direct e
Slide 15: Cash flow summary
Cash flow summary Operating leverage translating to cash generation 1 EBITDA Growth: EBITDA of $27.2m - a 68% increase from FY25 driven by continued fleet expansion, record sample volumes and the $000's FY25 FY26 increasing contribution of utilisation-led AAC EBITDA 1 16,134 27,168 2 Margin Expansio
Slide 16: Balance sheet
Balance sheet Strong balance sheet provides a solid platform to sustain growth #039;000 30-Jun-25 30-Jun-26 Assets Cash and cash equivalents 21,520 25,892 Trade and other receivables 2 27,707 33,123 1 Strong Balance Sheet to Support Growth: Strong balance sheet Other current assets (incl prepayments) 1
Slide 17: Strengthened funding capacity
Strengthened funding capacity Strategic funding to support growth Increased Funding Position $200m Syndicated Facility ■ Refinanced corporate facilities via new three-year A$200m syndicated facility 200 with three domestic financiers 175 ■ Shift from asset-based financing to a corporate-style struct
Slide 18: Strategy
Strategy [Insert]
Slide 19: Growing PhotonAssay technology adoption
Growing PhotonAssay technology adoption Expanding market penetration and growing engagement with the world’s leading miners Top 20 gold producing companies by 2025 production Recent endorsements Gold Fields 6% ● FY26: Northern Star became our first mining client to use Northern Star PhotonAssayTM as
Slide 20: The Opportunity
The Opportunity Vision: to become the world’s leading provider of innovative assay services and technologies Total Addressable Market (TAM)1 Convert gold mining projects in all key mining 700 hubs to PhotonAssayTM 610 Sites 600 Focus on improved customer outcomes to drive sample volumes 500 ~8%
Slide 21: Chrysos growth strategy
Chrysos growth strategy Disseminated market, now with a presence in every region Percentage of miners within total addressable market 13% ■ Established global footprint for PhotonAssayTM technology 13% supported by major global laboratory partners ■ Bureau Veritas agreement supports Chrysos’ deploym
Slide 22: PhotonAssay beyond gold
PhotonAssayTM beyond gold Unlocking further market opportunities Core market Additional revenue Long-term Non-gold focus → streams → Near-term R&D → potential → momentum Commercially Non-gold samples (’000) Available Detectable Elements • Base & energy metals • Rare earths 242 219 • Neutron analysis
Slide 23: Resilient multi-year growth outlook
Resilient multi-year growth outlook Fleet growth, production-linked volumes and a supportive gold price underpin durable earnings Driver 1 — Fleet scaling Driver 2 — Resilient demand Driver 3 — Lower earnings volatility Deployments support ~2x fleet over three years Industry maintaining elevated ass
Slide 24: FY27 Guidance and Outlook
FY27 Guidance and Outlook [Insert]
Slide 25: FY26 success derisks FY27
FY26 success derisks FY27 Broad-based industry acceptance across customers, partners and geographies Pillar 1 — Improving revenue visibility Pillar 2 — Existing fleet continues to mature Pillar 3 — Execution capability strengthened Contracted pipeline continues to strengthen Utilisation growth compl
Slide 26: PhotonAssay deployments
PhotonAssayTM deployments Global fleet supporting future growth Total PhotonAssayTM Units Deployed PhotonAssayTM Units Contracted PhotonAssayTM Units 54 → 59 +5 44 → 46 +2 83 → 87 +4 Units manufactured since May 2026 update Inclusive of one Ghanaian unit demobilised From May 2026 trading update to A
Slide 27: FY27 Guidance
FY27 Guidance Forecastable Revenue Model FY27 Guidance: ■ Total Revenue range of between $108m and $118m ■ EBITDA range of between $35m and $42m Note: Guidance set in August 2026 with constant currency assumptions (AUD:USD 0.6945 AUD:CAD 0.9627, AUD:GBP 0.522 AUD:EUR 0.6018 AUD:NZD 1.1923 AUD:GHS 8.
Slide 28: FY26 in summary
FY26 in summary Achieved upper end of FY26 guidance, and well-funded to support future growth Financial ■ Revenue of $88.1m, up 33% on FY25 ■ 68% growth in EBITDA to $27.2m Operational ■ 46 PhotonAssayTM units currently deployed ■ Seven units deployed in FY26 with a strong sales and manufacturing pi
Slide 29: The Chrysos investment proposition
The Chrysos investment proposition PhotonAssayTM is the mining industry’s most innovative assaying solution Delivering faster, safer, more accurate and environmentally-friendly gold analysis Non-discretionary spend Competitive fee-per-sample model for miners Long-term contracts Strong patent protect
Slide 30: Thank you
Thank you For more information, please visit chrysoscorp.com or contact us at investors@chrysoscorp.com
Slide 31: Appendix: About Chrysos
Appendix: [Insert] About Chrysos
Slide 32: Our commercialisation journey
Our commercialisation journey The outcome of 20+ years of research and development International Prototype Complete JORC and NI43-101 New Customer deployment continues 1st PhotonAssayTM Max unit Companies cite PhotonAssayTM Announcements Established Canadian & data in market announcements Barrick Bu
Slide 33: PhotonAssay technology
PhotonAssayTM technology Efficient, effective and environmentally-friendly minerals analysis Step 1 Step 2 Step 3 The crushed sample Automated high-energy X-ray Automated reporting (2-3 mm) is loaded into analysis, activates and detects gold atoms jars and scanned into Sample can be retained unit by
Slide 34: PhotonAssay Unit Development
PhotonAssayTM Unit Development The next generations of Chrysos’ PhotonAssay analysis Development focus: Supply chain resilience + Improved performance + Reduced maintenance PhotonAssayTM- XN: Even greater PhotonAssayTM - XC: The Aussie efficiency contender ■ A new generation of PhotonAssayTM units,
Slide 35: Delivering tangible benefits for miners
Delivering tangible benefits for miners PhotonAssayTM enables timely decision making and additional gold recovery The opportunity… PhotonAssayTM is embedded in the mining value chain PhotonAssayTM Value Add ■ Each year global miners are Exploration Fast turnaround for mine estimated to lose >$2.0 bi
Slide 36: Unit lifecycle & financial profile
Unit lifecycle & financial profile Unit economics are the underlying strength behind Chrysos’ business -18 Months -9 Months 8-12 weeks 5+5+5+5 year lease model 20 Years Long Lead Time • Detector station components Key steps Initial lease, renewal, recontract Refurbishment or re-use Components integr
Slide 37: Experienced leadership team
Experienced leadership team Supported by a well-respected and tenured board Senior leadership team Board of Directors Dirk Treasure Rob Adamson – appointed June 2016 Kerry Gleeson – appointed July 2021 Founding CEO & Managing Director Founder & Non-Executive Chairman Non-Executive Director • Metallu
Slide 38: Financial Appendix
HRYSOS ORF Financial Appendix
Slide 39: Strong tax balance sheet underpinning international growth
Strong tax balance sheet underpinning international growth Diversified global footprint — operations across ~12 tax jurisdictions $11.2m $2.97m 1 A strong tax balance sheet supporting the Group's high- growth trajectory, future earnings and sustainable cash tax Closing net deferred tax asset Current
Slide 40: Useful life reassessment extends the depreciation profile
Useful life reassessment extends the depreciation profile Component useful lives revised — change in accounting estimate effective 1 July 2026 10 → 15 yrs $18.6m Longer asset lives reduce the annual depreciation charge from FY2027, with no change to cash flow or asset carrying Weighted average usefu